Xolair Therapy Guidelines

Safety Protocols

The FDA requires observation for 2 hours after each of the first 3 injections due to anaphylaxis risk occurring in 0.09-0.2% of patients, with 61% of anaphylactic reactions (22/36 events) occurring within the first 2 hours after one of the first three doses 1
Patients must be trained in epinephrine autoinjector use and have one immediately available, as mandated by the FDA 1, 2
The FDA-mandated 2-hour observation period after Xolair injection is crucial, as anaphylactic reactions can occur in a small percentage of patients, highlighting the need for close monitoring 2

Evidence of proper informed consent discussion regarding anaphylaxis risk is necessary for Xolair therapy, as recommended by the Journal of Allergy and Clinical Immunology 2